Corcept Therapeutics Incorporated beat EPS estimates 62% of the time across 16 reported quarters (10 beats, 6 misses), averaging +8.3% versus consensus. Data sourced from SEC EDGAR.
| Quarter | EPS Estimate | EPS Actual | Surprise | Result | Call |
|---|---|---|---|---|---|
| Q2 FY26 | not reported | $0.36 | not reported | not reported | |
| Q1 FY26 | $-0.30 | $-0.30 | +0.0% | Beat | |
| Q4 FY25 | $0.27 | $0.20 | -25.9% | Miss | Q4 FY25 call |
| Q3 FY25 | $0.18 | $0.16 | -11.1% | Miss | |
| Q2 FY25 | $0.23 | $0.29 | +26.1% | Beat | |
| Q1 FY25 | $0.17 | $0.17 | +0.0% | Beat | |
| Q4 FY24 | $0.37 | $0.26 | -29.7% | Miss | |
| Q3 FY24 | $0.27 | $0.41 | +51.9% | Beat | |
| Q2 FY24 | $0.23 | $0.32 | +39.1% | Beat | |
| Q1 FY24 | $0.21 | $0.25 | +19.1% | Beat | |
| Q4 FY23 | $0.25 | $0.28 | +12.0% | Beat | |
| Q3 FY23 | $0.22 | $0.28 | +27.3% | Beat |
Back to CORT overview · CORT holders · CORT KPIs
Data sourced from U.S. SEC EDGAR filings. Not personalized investment advice.